Login to Your Account



Financings Roundup

AbbVie and Angels: Avaxia Closes $11M Series B for IBD

By Jennifer Boggs
Managing Editor

Monday, June 10, 2013
With data from the first clinical trial of anti-TNF polyclonal antibody AVX-470 in ulcerative colitis (UC) due toward the end of this year, Avaxia Biologics Inc. shored up its balance sheet with an additional $5 million, bringing its total Series B funding to $11.4 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription